[01]
Continuity Overview
ACTIVE TRANSITION // NODE #04

Chief Scientific Officer Handover

Acme BioSystems Discovery Division • Aman Kumar → Marcus Vance

STATUS: CALCULATINGREADINESS: 0%
OUTGOING AUTHORITY:Aman KumarRelinquishing IND Filings & Trial Protocol Sign-Off
INCOMING SUCCESSOR:Marcus VanceIncoming Head of Translational Oncology
IMMINENT BLOCKER:Loading blockers...Synchronizing ledger...
DEPOSITED RECORDS
0 DOCS

Charters, MSAs, minutes

INDEXED TRIPLES
0 ENTITIES

100% citation linked

OPEN ANOMALIES
0 FLAGGED

Requires Switch review

READINESS SCORE
0% READY

Continuity threshold

CONTINUITY VULNERABILITY INDEX:TARGET ≥ 80% (CURRENT: 0%)

Critical Unresolved Matters & Discrepancies

Anomalies requiring human adjudication at the Switch review desk

CASE-BIO-09

FDA Form 1572 Principal Investigator Sign-Off Mismatch

Conflicting Evidence

Vendor MSA Amendment 3 names Dr. Marcus Thorne as sponsor representative, while FDA Form 1572 lists Dr. Eleanor Vance. Discrepancy risks clinical hold on Phase II Oncology trials.

SOURCE: Regulatory-Audit-Q3-2024.pdf (p. 14)Resolve in Switch →
CASE-BIO-14

$140,000 Spectrometry Lab Contract Auto-Renewal

Missing Record

Automatic 12-month renewal triggers on November 15, 2024 unless written opt-out is delivered by October 15. Sign-off authority is unassigned in the transition charter.

SOURCE: Vendor-Master-Agreement-2023.docx (Sec. 8.2)Resolve in Switch →

Quick Ingestion Dock

LOCAL INTAKE BUFFER
Deposit Institutional Records

Select or drag PDF, DOCX, TXT archives • Max 25MB per file

CONTINUITY MODULES

Workspace Navigation

• Local SQLite database (WAL)

• Direct SHA-256 integrity verification